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Objectives: To map the integration of existing maternal tetanus immunization programmes within ante-
natal care (ANC) services for pregnant women in low- and middle-income countries (LMICs) and to iden-
tify and understand the challenges, barriers and facilitators associated with high performance maternal
vaccine service delivery.
Design: A mixed methods, cross sectional study with four data collection phases including a desk review,
online survey, telephone and face-to-face interviews and in country visits was undertaken between 2016
and 2018. Associations of different service delivery process components with protection at birth (PAB) and
withcountry groupswere established. PABwasdefinedas theproportionofneonatesprotectedatbirthagainst
neonatal tetanus. Regression analysis and structural equationmodellingwas used to assess associations of dif-
ferent variableswithmaternal tetanus immunization coverage. Latent class analysis (LCA), was used to group
country performance for maternal immunization, and to address the problem of multicollinearity.
Setting: LMICs.
Results: Themajority of LMICs had a policy on recommended number of ANC visits, howevermostwere yet to
implement theWHOguidelines recommendingeightANCcontacts. Countries that recommended>4ANCcon-
tactsweremore likely to have high PAB > 90%. Passive disease surveillancewas themost common form of dis-
ease surveillance performed but the maternal and neonatal morbidity and mortality indicators recorded
differed between countries. The presence of user fees for antenatal care and maternal immunization was sig-
nificantly associated with lower PAB (<90%).
Conclusions: Recommendations include implementing the current WHO ANC guideline to facilitate increased
opportunities for vaccination during each pregnancy. Improved utilisation of ANC services by increasing the
demand side by increasing the quality of services, reducing any associated costs and supporting user fee
exemptions, or the supply side can also enhance utilisation of ANC services which are positioned as an ideal
platform for delivery of maternal vaccines.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).
M.L. Giles et al. / Vaccine 38 (2020) 5278–5285 52791. Background
In 2015, an estimated 303,000 women died from pregnancy-
related causes [1], and 2.6 million babies were stillborn [2]. In
2017 an estimated 2.5 million babies died in the first month of life
[3]. Many of these deaths would be preventable through increased
access to and use of quality health care during pregnancy and
childbirth. Building on the progress made by the Millennium
Development Goals (MDGs) in 2015, the Sustainable Development
Goals (SDG) were launched to guide the eradication of poverty,
hunger, illiteracy, and disease [4]. The third SDG on good health
and wellbeing, aims to end preventable deaths of newborns and
children under five years of age by 2030, with a target to further
reduce neonatal mortality to at least as low as 12 per 1,000 live
births and under five mortality to at least as low as 25 per 1,000
live births [5]. Infectious diseases, particularly pneumonia and sep-
sis are leading causes of death in children under five years of age
[6], some of which may be preventable by maternal immunization.
Deaths during the neonatal period constitute almost 50% of the
total deaths occurring in children under five years, with little pro-
gress made in the past decades [7]. The Maternal and Neonatal
Tetanus Elimination (MNTE) initiative, launched in 1989, was the
first maternal immunization programme to be recommended glob-
ally [8]. Along with safe birthing practices this has contributed to
over 700,000 lives saved and as of today only 13 countries have
yet to eliminate maternal and neonatal tetanus [8]. Other vaccines
being recommended during pregnancy include influenza and in
many high-income settings pertussis [9–15]. For vaccination to
be an effective intervention strategy during pregnancy, it relies
on access to health care during pregnancy, maternity care provi-
ders recommending the intervention, women understanding and
accepting the intervention, and vaccination of the pregnant
woman.
Antenatal care (ANC) is accepted as the natural entry point for
interventions during pregnancy, such as maternal immunization,
and provides important opportunities for the prevention, identifi-
cation and treatment of diseases affecting pregnant women and
their babies. Despite progress made in ANC utilization, UNICEF
estimates that in 2010–2016, only 61.8% of women globally
received at least four antenatal care visits [16]. This figure is even
lower in regions with the highest rates of maternal and perinatal
mortality, such as sub-Saharan Africa (52%) and South Asia (46%)
[16]. Not only is the number of contacts during pregnancy impor-
tant but also the timing of the first ANC visit. Ensuring the first ANC
visit is in the first trimester, is essential to optimising health out-
comes for women and children. Global estimates between 1990
and 2013 report early ANC visit as 24% in low income countries
compared to 82% in high income countries [17]. In 2016, the World
Health Organization (WHO) issued new recommendations to
improve ANC and to reduce the risk of stillbirths and pregnancy
complications [18]. Central to these new recommendations is the
focus on a minimum of eight contacts during pregnancy and one
ultrasound scan before 24 weeks of gestation, ensuring a healthy
pregnancy for mother and baby leading to a positive birth and
motherhood experience [18].
In addition to tetanus and influenza, there are new maternal
vaccine candidates in development such as against respiratory syn-
cytial virus (RSV) and group B streptococcus (GBS). In low- and
middle-income countries RSV and GBS account for a significant
burden of disease [19,20]. RSV is the most important cause of viral
lower respiratory tract disease in infants globally. In a systematic
review, it was estimated that in 2015 RSV infection was responsi-
ble for 33.1 million episodes of RSV acute lower respiratory infec-
tion, resulting in 1.4 million hospital admissions in children less
than six months of age and 27,300 in-hospital deaths, a significant
proportion of these in the first month of life [19]. GBS is an impor-tant cause of neonatal sepsis and meningitis, particularly in the
first 3 months of life. In 2015, there were an estimated 90,000
deaths in infants less than three months of age, 57,000 fetal infec-
tions and/or stillbirths (defined as a dead borne fetus
weighing > 1000gm and/or > 28 weeks gestational age and/or body
length of 35 cm) and 33,000 cases of invasive GBS disease in preg-
nant or post-partum women (including endometritis, chorioam-
nionitis and sepsis) [20].
If these vaccine candidates prove to be safe and efficacious they
may be recommended for pregnant women in the future. In antic-
ipation of this, there is an urgent need to describe the current land-
scape of antenatal care service provision and better understand the
optimal ways to deliver vaccines, including the value of using ante-
natal care services as a delivery platform.
The WHO, supported by the Bill & Melinda Gates Foundation,
commenced work in mapping strengths of existing maternal teta-
nus immunization programmes through the Maternal Immuniza-
tion and Antenatal Care Situational Analysis (MIACSA) project.
This project aims to identify and understand the challenges from,
barriers to and facilitators of successful maternal immunization
in low- and middle-income countries (LMICs) [20]. This project
also sets out to develop a typology of existing health systems in
terms of vaccine delivery strategies to pregnant women and the
attributes associated with high performance maternal vaccine ser-
vice delivery in LMICs. An important goal is to identify what
aspects of antenatal care need to be strengthened and what gaps
need to be addressed to inform the introduction of additional
maternal vaccines particularly into antenatal care services.2. Methods
2.1. Study design and data collection
A detailed overview of the project methodology has been pub-
lished previously [21]. In summary, between November 2016 and
September 2018, a mixed methods cross sectional study was car-
ried out with four components. The four components did not run
for the entire study period between 2016 and 2018, although there
was considerable overlap in time of data collection between Phase
III and IV. These four components are briefly summarised below.
(1) Phase I - A desktop review of pre-defined maternal and child
health indicators and World Bank Data for economic level in
137 low- and middle income countries (LMICs)
The following databases were used to extract data;
Demographic and Health Surveys (DHS)/Multiple Indicator Cluster
Surveys (MICS), WHO/United Nations Children’s Fund (UNICEF)
estimates of national immunization coverage, WHO/UNICEF Joint
Reporting Forms (JRF), Maternal Neonatal Tetanus Elimination
(MNTE) database, WHO Maternal, Newborn, Child, and Adolescent
Health (MNCAH) policy surveys, GAVI web page for eligibility, Uni-
ted Nations (UN) Inter-agency Group for Child Mortality Estima-
tion, trends in maternal mortality: 1990 to 2015 and United
Nations, Department of Economic and Social Affairs, Population
Division. The number of countries in the databases and time peri-
ods reviewed varies. The information used in this analysis is based
on the most recent surveys at the time of the analysis.
(2) Phase II - Global online survey sent to 116 LMICs
An 18-item online survey was developed collecting data on ser-
vice delivery models of maternal tetanus vaccination, programme
funding, disease surveillance, vaccine safety surveillance and
maternal vaccines other than tetanus. The survey was not sent to
5280 M.L. Giles et al. / Vaccine 38 (2020) 5278–5285the WHO European region which decided not to participate in this
project because the MNTE initiative is not a priority there.
(3) Phase III - Telephone and face to face interviews
A 91-item survey was developed by the MIACSA Expert Advi-
sory Panel. The telephone interview was pilot tested in two coun-
tries (Sri Lanka and Tanzania), and thereafter adapted based on
participant comments and administered via in-depth telephone
and face-to-face interviews with Expanded Programme on Immu-
nisation (EPI) and Maternal, Newborn and Child health (MNCH)
programme officers in a sample of countries. Data from the pilots
was included in the final analysis. Of the 26 interviews, 21 were
completed entirely over the phone. The remaining 5 were com-
pleted partly or fully in country. These included Ethiopia, Fiji, Bhu-
tan, Thailand and Morocco.
(4) Phase IV- In-country visits
In-country visits were conducted in ten selected countries.
Countries were identified based on a system developed by the
researchers to stratify countries into four groups according to
maternal tetanus vaccination performance measured as protection
at birth (PAB) and antenatal care performance (measured as ANC4+
coverage). A cut-off of PAB of 90% was used to divide countries into
high and lowmaternal tetanus vaccination performers. For antena-
tal care performance, high and low performance was defined as
either above or below the median ANC4+ coverage. The final coun-
try selection tried to ensure representation from all WHO regions,
including high-performing countries, MNTE priority countries and
countries with high ANC4+ coverage. Data collected included from
in depth key informant interviews, focus group discussions, and
health care facility observations. In each country, between 6 and
14 health facilities, identified by the Ministry of Health, were
visited.
2.2. Key definitions
PAB: is the proportion of neonates protected at birth against
neonatal tetanus, by combining data on the number of tetanus vac-
cine doses received by the mother by the last baby born, interval
between doses, and time since last dose (using card or verbal his-
tory). PAB was used as dichotomous variable: low: PAB < 90% vs.
high: PAB>=90%.
ANC performance: The proportion of pregnant women who
attended at least one ANC visit during their last pregnancy
(ANC1) and the proportion of pregnant women who attended four
or more ANC visits during their last pregnancy (ANC4+) were used.
EPI performance: Data from the desk review on Diphtheria-
Pertussis-Tetanus (DPT)/third dose of pentavalent (Penta3) vacci-
nes were used.
TT2+: Proportion of pregnant women receiving at least two
doses of Tetanus toxoid containing vaccine
2.3. Statistical analysis
All data were imported into STATA V.15 (StataCorp LCC, Texas)
for analyses. All analyses were conducted using non-missing data.
Summary measures (proportions, means, medians and standard
errors) were obtained for all variables of interest.
Countries were then grouped in two ways; (1) according to high
and low-PAB coverage and (2) according to selected MNCH and EPI
performance indicators. In order to create country groups based on
a combination of MNCH and EPI performance indicators, latent
class analysis (LCA), was used to enable the characterization of
an unobserved (latent) variable through analysis of the structureof the relationship among several observed variables [22]. LCA
allowed multiple indicators to simultaneously contribute to the
definition of country groups. LCA therefore was able to address
the problem of multi-collinearity. The variables included in the
LCA model included PAB, TT2+, DPT3, ANC1, ANC4+, neonatal mor-
tality rate and maternal mortality rate. The LCA generated four
country groups defined as;
Group 1: Currently very limited potential to protect mothers
and their young children from vaccine-preventable infections
(limited ANC and EPI performance)
Group 2: Limited potential to protect mothers and their young
children from vaccine-preventable infections (moderate ANC
and EPI performance)
Group 3: Moderate potential to protect of mothers and their
young children from vaccine-preventable infections (mostly
successful ANC and EPI performance)
Group 4: High potential for protection of mothers and their
young children from vaccine-preventable infections (successful
ANC and EPI performance)
Fisher’s exact test was used to establish differences in service
delivery process components (1) by PAB coverage (PAB < 90% vs.
PAB>=90%) and (2) by country groups (Group 1 vs. others; Group
2 vs. others; Group 3 vs. others; Group 4 vs. others).3. Results
The online survey (sent to 116 LMIC countries) was answered
by 97 countries, of which two provided incomplete responses.
Twenty-six countries participated in the telephone survey, and
week-long in-country visits took place in ten countries. A total of
96 health facility visits and interviews with health facility man-
agers occurred during the in-country visits (Fig. 1).3.1. Antenatal care policy and targets
Based on Phase I (the desk review), information on theminimum
number of recommended antenatal visits containedwithin the ANC
policy was available for 122/137 (89%) countries (see Fig. 2).
Based on Phase II (the online survey), 88/95 (93%) countries
provided information on minimum number of recommended
ANC visits. Among these 88 countries, 15 (17.0%) recommended
eight or more visits in line with the new WHO recommendation,
while 15 (17.0%) countries recommended between five and seven
visits. Fifty-seven countries reported having a policy of four visits
(64.7%), the remaining had three visits.
Countries with a policy recommending > 3 ANC visits were
more likely to have higher PAB coverage (>=90% vs < 90%, Fisher’s
exact P-value = 0.020). A policy of > 4 ANC visits was also more
common among group 3 (high potential) countries (Fisher’s exact
P-value < 0.001) and less common among group 2 (limited poten-
tial) countries (Fisher’s exact P-value 0.001).3.2. Antenatal care service delivery including number of visits, timing
of visits and outreach
Although nearly all countries had a policy on the recommended
minimum number of visits during pregnancy, few countries
(12/26; 46.2%) which responded to the telephone interview were
able to provide data on the proportion of women who attended a
predefined number of visits including the respective timing of
these visits. The number of women never accessing ANC services
was considerable among countries with very limited to limited
Phase I
Desk review
Phase II
Online Survey
Phase III
Telephone and
face-to-face 
interviews
Phase IV
In country visits
137 LMICs
116 LMICs
26 LMICs
10 LMICs
97 responses
(two incomplete)
Benin, Bhutan, Botswana, Cameroon, 
Democrac Republic of the Congo (DRC), 
Republic of Congo, Colombia, Costa Rica, 
Dominica, Egypt, Ethiopia, Fiji, Gabon, 
Malawi, Morocco, Nicaragua, Niger, 
Pakistan, Papua New Guinea, Senegal, Sierra 
Leone, South Sudan, Sri Lanka, Thailand, 
Tanzania, Uganda
Benin, Bhutan, Ethiopia, 
Fiji, Gabon, Morocco, 
Panama, Senegal, Tanzania 
and Thailand
Fig. 1. Four phases of the project and number of countries participating.
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Fig. 2. Percent of countries with a policy of >4 ANC visits. Data from online survey among 88 countries. Group 1 = very limited potential to protect mothers and young
children against vaccine-preventable diseases, Group 2 = limited potential, Group 3 = moderate potential, Group 4 = high potential, PAB = protection at birth. Fisher’s Exact P-
values: * <0.05, *** <0.001.
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ventable diseases, 35% and 7% respectively (Fig. 3).
Importantly, countries recommending > 4 antenatal visits were
more likely to have high performance for maternal tetanus immu-
nization defined as PAB > 90% (p = 0.02) and were more likely to be
group 4 countries (high potential for protection of mothers and
their young children from vaccine-preventable infections)
(p = 0.001).
All countries provided ANC services at fixed health facilities.
Government outreach programmes were offered in 55/95 (57.9%)
countries, including ANC services. This was more common amonggroup 2 (limited potential) countries (Fisher’s exact p-value 0.078)
and less in group 4 (high potential, p-value 0.067), but the differ-
ence was only marginally significant (Table 1). There was no asso-
ciation with PAB coverage.
More detailed information about the provision of outreach ser-
vices was available from the telephone interviews with 26 coun-
tries. Among the countries participating in the telephone
interviews, six countries provided mobile or outreach services
specifically for ANC; in eight countries ANC was included in other
outreach activities, and seven countries provided both. During
country visits, wide variation was observed in the content and
Fig. 3. Percentage of women with 0, 1–3, or 4 or more ANC visits according to the most recent national data available, by country group (telephone survey, N = 26).
Table 1
Government outreach programmes offering ANC services. Data from online survey, 95 countries.
Outreach, ANC PAB < 90% PAB>=90 Group 1 Group 2 Group 3 Group 4 Total
No 18 (40) 14 (37.8) 6 (54.5) 9 (28.1) 10 (38.5) 15 (57.7) 40 (42.1)
Yes 27 (60) 23 (62.2) 5 (45.5) 23 (71.9) 16 (61.5) 11 (42.3) 55 (57.9)
Total 45 (1 0 0) 37 (1 0 0) 11 (1 0 0) 32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
Fisher’s exact P-value 1 0.518 0.078 0.816 0.067
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a given country. Additionally, the majority of ANC outreach in
countries visited provided a limited package of ANC services,
including some or all of the following elements: blood pressure
measurement, iron and folic acid supplementation, malaria pro-
phylaxis (where applicable), counselling, prevention of mother-
to-child transmission of HIV and referral of women to the nearest
health facility for laboratory testing.Fig. 4. Percentage of countries reporting different ANC funding sources, informa-
tion from telephone interviews (24 countries).3.3. ANC service package and quality of antenatal care
According to the telephone interviews 14/22 (63.6%) countries
provided at least 11 different ANC interventions in their ANC ser-
vice package. The list of ANC interventions asked about included
counselling on diet, iron and folic acid supplementation, vitamin
A supplementation, screening for; anemia, urinary tract infection/
bacteriuria, intimate partner violence, gestational diabetes,
tobacco use, substance abuse, HIV, syphilis and tuberculosis, sym-
physis fundal measurement, ultrasound scan for gestational age
estimation and screening for birth defects, antibiotic prophylaxis
for prevention of recurrent urinary tract infections, screening for
blood type and Rh, administration of anti-D, preventive anthel-
minthic treatment, intermittent preventive treatment during preg-
nancy (IPTp) for malaria, pre-exposure prophylaxis for HIV
prevention (PrEP), counselling on danger signs in pregnancy, and
birth planning. Four countries didn’t respond to the question. The
three most common services offered by more than 90% of the
health facilities visited, were iron and folic acid supplementation,
dietary counselling, and screening for HIV. The country visits
revealed a higher number of interventions offered in the ANC pack-
age in high potential countries (group 4 countries mentioned on
average 12.5 essential interventions compared to 9 in the other
countries, P–value fromWilcoxon rank sum test = 0.010, telephone
interviews).The existence and functioning of the ANC referral systems was
explored in both the telephone interviews with 26 countries and
the visits to 96 facilities during the country visits. National level
programme managers from 25/26 countries that provided infor-
mation through telephone interviews reported having a functional
ANC referral system in place for high risk or complicated deliveries.
Of the 96 facilities visited, 92 (95.8%) reported having a system in
place for referring pregnant women to a higher level of care. The
four facilities that did not report referring women were themselves
reference hospitals and, thus, did not initiate referrals.3.4. Funding sources and ANC coverage and quality
Most countries responding to the telephone interviews (23/24;
95.8%) reported that funding for ANC was dependent primarily
upon the national budget, while 12/24 (50%) countries also benefit-
ted from external donor funding for ANC (Fig. 4). Overall, one in
five countries indicated that ANC services were partly funded by
out-of-pocket payments.
Fig. 5. Percent of countries performing different types of disease surveillance for
maternal and neonatal tetanus, data from online survey in 95 countries.
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exemptions for ANC and for maternal tetanus immunization. In
72/95 countries (75.8%), pregnant women were exempt from
ANC user fees, and in all but one country, maternal tetanus immu-
nization was free. In 12/95 (12.6%) countries, user fee exemptions
for ANC were in place only for some groups in the population and
in 11/95 (11.6%) countries, no user-fee exemptions existed. The
imposition of user fees for antenatal care services was significantly
associated with lower PAB coverage (Fisher’s exact p-value 0.037).3.5. Disease surveillance
Passive surveillance was the most common form of disease
surveillance performed (Fig. 5). The morbidity and mortality indi-
cators, which were recorded, differed between countries (Table 2).
According to the online survey, most common were surveillance
for neonatal tetanus (91/95; 96%) and maternal deaths (84/95;
88%). Maternal and neonatal deaths were less often recorded in
group 1 countries (Fisher’s exact p-value 0.003 and 0.045, respec-
tively). Surveillance for congenital rubella, neonatal deaths and
neonatal sepsis was less common overall, but more common in
group 4 countries (high potential to protect mothers and their
young children from vaccine-preventable infections). In terms ofTable 2
Disease surveillance (online survey, 95 countries).
a - Neonatal tetanus
PAB < 90% PAB>=90 Group 1
No 2 (4.4) 0 (0) 1 (9.1)
Yes 43 (95.6) 37 (1 0 0) 10 (90.9)
45 (1 0 0) 37 (1 0 0) 11 (1 0 0)
Fisher’s exact 0.499 0.394
b -Congenital rubella syndrome
No 22 (48.9) 9 (24.3) 7 (63.6)
Yes 23 (51.1) 28 (75.7) 4 (36.4)
45 (1 0 0) 37 (1 0 0) 11 (1 0 0)
Fisher’s exact 0.039 0.045
c -Neonatal sepsis
No 35 (77.8) 25 (67.6) 9 (81.8)
Yes 10 (22.2) 12 (32.4) 2 (18.2)
45 (1 0 0) 37 (1 0 0) 11 (1 0 0)
Fisher’s exact 0.327 0.493
d. -Neonatal deaths
No 16 (35.6) 4 (10.8) 5 (45.5)
Yes 29 (64.4) 33 (89.2) 6 (54.5)
45 (1 0 0) 37 (1 0 0) 11 (1 0 0)
Fisher’s exact 0.011 0.050
e -Maternal deaths
No 8 (17.8) 3 (8.1) 5 (45.5)
Yes 37 (82.2) 34 (91.9) 6 (54.5)
45 (1 0 0) 37 (1 0 0) 11 (1 0 0)
Fisher’s exact 0.330 0.003private facilities reporting cases of tetanus, 16/26 (62%) countries
confirmed that they report tetanus cases.4. Discussion
The results from the MIACSA project in LMICs demonstrate that
for maternal tetanus immunization, the majority of countries
despite having a policy on recommended number of ANC visits,
had yet to implement the WHO guidelines recommending eight
antenatal contacts [18]. Importantly, countries recommending > 4
antenatal visits were more likely to have high performance for
maternal tetanus immunization defined as PAB > 90% and were
more likely to be group 4 countries (high potential for protection
of mothers and their young children from vaccine-preventable
infections).
If future maternal vaccines are to be delivered to pregnant
women via the ANC platform then ANC service delivery compo-
nents including the number of contacts and timing of contacts
are important. Somematernal vaccines may require administration
during particular gestational windows, such as RSV vaccine (clini-
calTrials.gov NCT02624947) so a system’s capacity to record timing
of ANC visits is important for identifying gaps and targeting cam-
paigns to maximise attendance at recommended time frames to
optimise implementation of maternal immunization during ANC.
The WHO antenatal care guidelines concentrate most of the eight
recommended contacts in the third trimester. Indicators about
the frequency of visits are frequently collected, but the findings
from the MIACSA project highlight that information about the tim-
ing of ANC visits by trimester is rarely available and needs to be
included in future monitoring efforts, should new maternal vacci-
nes require a specific time window for administration. Given the
potential importance of accurately estimating gestational age,
and potentially narrow gestational windows for future maternal
vaccines such as RSV, it is crucial that policy makers and those
involved in implementation of new vaccines understand the rele-
vance of this data, and invest in and build robust systems for cap-
turing this data.Group 2 Group 3 Group 4 Total
0 (0) 1 (3.8) 2 (7.7) 4 (4.2)
32 (1 0 0) 25 (96.2) 24 (92.3) 91 (95.8)
32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
0.297 1.000 0.301
14 (43.8) 8 (30.8) 4 (15.4) 33 (34.7)
18 (56.3) 18 (69.2) 22 (84.6) 62 (65.3)
32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
0.254 0.809 0.016
27 (84.4) 16 (61.5) 13 (50) 65 (68.4)
5 (15.6) 10 (38.5) 13 (50) 30 (31.6)
32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
0.020 0.459 0.026
9 (28.1) 5 (19.2) 1 (3.8) 20 (21.1)
23 (71.9) 21 (80.8) 25 (96.2) 75 (78.9)
32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
0.288 1.000 0.011
3 (9.4) 2 (7.7) 1 (3.8) 11 (11.6)
29 (90.6) 24 (92.3) 25 (96.2) 84 (88.4)
32 (1 0 0) 26 (1 0 0) 26 (1 0 0) 95 (1 0 0)
0.745 0.722 0.279
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reduce perinatal and maternal mortality. Transitioning to eight vis-
its will likely help reduce the missed opportunities for vaccination
and other life-saving interventions due to increased contacts with
pregnant women. Early ANC contact is essential to screen for and
prevent or treat any important morbidities as early as possible,
assess risk of developing pregnancy related complications and plan
for relevant interventions as well as establish gestational age more
accurately, while more frequent visits in the latter part of the preg-
nancy may assist with immunization coverage and reducing still-
births [23,24]. Populations with suboptimal access early in
pregnancy (some due to geographical remoteness or women not
recognising the need for care early in pregnancy) provide addi-
tional challenges to antenatal care service delivery. Countries
struggling to raise TT2 + coverage often have dispersed popula-
tions. In these settings outreach services are extremely important
but often under-resourced.
Whilst building robust systems to capture data on timing and
number of antenatal contacts, consideration should be given to a
coordinated approach across information systems. In-particular,
improvements in tracking, reporting, linkage of mother and child
records, and surveillance systems for maternal and neonatal mor-
bidity and mortality would enable planning for the introduction of
additional maternal vaccines in the future.
Uncertainty about assessing quality of antenatal care notwith-
standing, the issue of out-of-pocket expenses for women is rele-
vant to the quality of antenatal care and attendance for the
recommended minimum number of antenatal visits. The presence
of user fees was significantly associated with lower PAB coverage.
This is likely because user fees may be a disincentive for women to
access healthcare services. If increased utilisation of ANC services
is required to maximise the opportunities for women to receive
maternal vaccines, then any disincentives such as out of pocket
expenses need to be addressed. In addition, hidden costs for
women such as transport to and from the facilities and long wait-
ing times may further discourage utilization of antenatal care ser-
vices. In the MIACSA project, out of pocket expenses did not
necessarily apply to vaccination but to other antenatal care ser-
vices such as pathology or ultrasound as well as cost for trans-
portation. In all but one of the 95 countries surveyed online,
maternal immunization in the public system incurred no cost to
the woman. However, the free cost of the vaccine was undermined
in instances when the woman accessed the vaccine through ANC
services for which there were out-of-pocket expenses.
A well-functioning disease surveillance system for both mater-
nal and neonatal mortality and morbidity is crucial to inform the
need and performance of any existing or future vaccine pro-
gramme. Based on the findings from the MIACSA project there is
significant variability, depending on the setting, on the range of
diseases covered by surveillance and often a complete absence of
a surveillance system for outcomes such as stillbirth. These gaps
and inconsistencies identified by the MIACSA project highlight
the need to strengthen capacity for both maternal and neonatal
disease surveillance in parallel with strengthening antenatal care
service delivery. These systems are essential to the planning,
implementation and the evaluation of any future public health ini-
tiative such as a new maternal immunization programme.
The study methodology has several limitations. The different
data sources used in the MIACSA project meant that inconsisten-
cies between the different databases were observed for some
quantitative and policy-related indicators. This may have been
due to collection of information at different time-points, inconsis-
tent definitions across sources, or different sampling methodolo-
gies. Besides different sources of data, inaccurate reporting
cannot be fully excluded despite efforts made by the countries to
validate the information provided to the study team. Another lim-itation was the relatively small number of countries visited, and of
health facilities by country. Health facilities visited were not ran-
domly selected but were assigned by the Ministries of Health. They
are not therefore necessarily representative of the entire country
but rather reflect a potentially higher-performing part of the health
system within a particular country.5. Conclusion
The MIACSA project has identified aspects of maternal tetanus
immunization that need to be strengthened and gaps that need
to be addressed to inform the introduction of additional maternal
vaccines particularly into antenatal care services. Specific recom-
mendations arising from the MIACSA project include;
 Increasing the number of countries adopting the current WHO
recommendation for eight antenatal contacts thereby increas-
ing opportunities for vaccination during pregnancy
 Introducing record keeping systems that are able to identify the
number of visits women attend during pregnancy
 Introducing record keeping systems that are able to identify the
timing of visits during pregnancy (not just total number)
 Reducing any associated costs for ANC and supporting user fee
exemptions for all vulnerable women
 Introducing maternal and neonatal disease surveillance systems
(including for stillbirth) consistently across all LMICs
It is recognised that these recommendations require a substan-
tial financial and political commitment depending on the individ-
ual country context. In addition, these recommendations may be
prioritised differently according to existing country context, record
keeping systems, surveillance systems and models of antenatal
care. However, it is envisaged that policy makers and program
managers for immunization and antenatal care programs are
encouraged to consider these and contemplate how they can be
addressed in their local setting.
It is hoped that with implementation of these recommendations
a stronger ANC system will prevail leading to improved utilisation
of ANC services. This in turn provides greater opportunities to vac-
cinate pregnant women with the currently recommended mater-
nal vaccines and a robust platform for the introduction of new
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